SCHEMBL31419703

SCHEMBL31419703

CC(C)(C)OC(=O)N1CCCCC(C(=O)Nc2nc3c(F)cc(F)cc3s2)C1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.61
▸ RAB9A P51151 6/20 0.61
▸ CHKA P35790 1/20 0.47
▸ LMNA P02545 2/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ POLB P06746 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ USP2 O75604 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ ABL1 P00519 1/20 0.43
▸ RIN1 Q13671 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ AGTR1 P30556 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31389071 0.97 NPC1 (0.62) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL31200451 0.97 NPC1 (0.62) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL25528395 0.97 NPC1 (0.62) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL25209406 0.97 NPC1 (0.62) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL31389076 0.97 NPC1 (0.62) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL24071502 0.97 NPC1 (0.62) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL24071450 0.94 NPC1 (0.65) NPC1RAB9ACHKALMNAALDH1A1
SCHEMBL31419700 0.90 RAB9A (0.52) NPC1RAB9ACHKALMNAMAPK1
SCHEMBL31419727 0.89 NPC1 (0.56) NPC1RAB9ACHKALMNAALDH1A1
SCHEMBL31200507 0.89 NPC1 (0.58) NPC1RAB9ACHKALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092030-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2025-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092030-A1 ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A PDE2A, GUCY1A1, GCGR NPC1 1065/4885RAB9A 960/4885CHKA 2381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback